Abstract 1938P
Background
Magnitude of clinical benefit from drugs used in tumours must be evaluated using validated and reproducible tools. European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS) and American Society for Medical Oncology (ASCO) Value Framework (ASCO-VF) are the most important. Here, we evaluate characteristics and outcomes of clinical trials supporting drugs used in STS and BS, and their association with ESMO-MCBS and ASCO-VF.
Methods
We reviewed publications between January 1988 and December 2022 that support the recommendations of NCCN guidelines version 1.2023 for STS and 3.2023 for BS (gastrointestinal stromal tumours were excluded). We collected data regarding trial characteristics, efficacy, toxicity and quality of life (QoL). ESMO-MCBS and ASCO-VF were applied. Substantial clinical benefit was defined as a grade 4 or 5 (in a scale from 1 to 5) for ESMO-MCBS and a ≥45 for ASCO-VF.
Results
We identified 119 studies (71 for STS and 48 for BS) that support the use of 49 drugs or combinations. ESMO-MCBS could be applied in 58 trials (48.7%). Of them, 37 (64%) were single arm and 21 (36%) randomized clinical trials (RCT; 13 phase III and 8 phase II). ASCO-VF could only be applied in 10 of the previously described (6 phase III and 4 phase II RCT). QoL was reported in 17.2% (10/58), all published beyond 2011. Among these, only 1 (10%) showed improvement in QoL. Only 33.3% of RCT (7/21) demonstrated improvement in overall survival. Ten (17.2%) trials, all of them RCT, met the ESMO-MCBS substantial benefit threshold (7 involving STS and 3 BS). Only 4 of these met the ASCO-VF criteria (all for STS). Spearman’s correlation coefficient between scales was 0.65.
Conclusions
Less than half of the studies supporting the NCCN recommendations for the prescription of drugs in advanced sarcomas can be evaluated using validated scales to assess the magnitude of their clinical benefit. Substantial clinical benefit was only achieved in a minority of those. QoL analysis should be incorporated in further studies to better evaluate their actual clinical benefit. Correlation among ESMO-MCBS and ASCO-VF was noteworthy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1840P - RNASEH2B loss and PARP inhibition (parpi) in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Juliet Carmichael
Session: Poster session 15
1841TiP - Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Presenter: Alicia Morgans
Session: Poster session 15
1842TiP - Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
Presenter: Johann de Bono
Session: Poster session 15
1922P - Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study
Presenter: Nadia Hindi Muñiz
Session: Poster session 15
1923P - Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma
Presenter: Yoichi Naito
Session: Poster session 15
1924P - Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
Presenter: Cheng-Ming Sun
Session: Poster session 15
1925P - Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Presenter: Neal Chawla
Session: Poster session 15
1926P - Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
Presenter: Javier Martin-Broto
Session: Poster session 15
1927P - Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Presenter: Axel Le Cesne
Session: Poster session 15
1928P - Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
Presenter: Jean-Yves Blay
Session: Poster session 15